- DXS 48 Grafton Street Manchester M13 9XX United Kingdom
- 0161 606 7201
- 0161 606 7313
9 September 2009 - DXS has announced the appointment of Dr Patrik Dahlen as non-executive director.
DXS has entered into a collaboration agreement with Bristol-Myers Squibb Company and Imclone Systems to further develop a K-RAS companion diagnostic for Erbitux (cetuximab) in the US and Canada.
DXS is working with Astrazeneca to make available a companion diagnostic for use with Iressa (gefitinib), Astrazeneca's treatment for non small cell lung cancer (NSCLC).
Horizon will develop a panel of human isogenic cell models that recapitulate key drug sensitivity and resistance mechanisms in cancer patients.
DxS and Epigenomics AG have cross-licensed certain technologies, enabling them to develop and sell in vitro diagnostic (IVD) products, based on DNA methylation, that utilise DxS' Scorpions technology.